The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...

(The Guardian) The FDA expanded indications for brentuximab vedotin (Adcetris) to include use in combination therapy for relapsed/refractory large B-cell lymphoma that has progressed on at least two ...

Seagen was a pioneer in the development of ADC drugs, and has successfully brought two to market – Adcetris (brentuximab vedotin) for various type of lymphoma and Padcev (enfortumab vedotin ...

The Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) in combination with Revlimid (lenalidomide) and Rituxan (rituximab) for the treatment of adults with relapsed or ...

The FDA approved two new oncology drugs last month. Here's Here’s a summary of those approvals and what else happened in ...

In her budget speech, Finance Minister Nirmala Sitharaman announced the exemption of 36 drugs used to treat cancer, rare diseases, and other severe chronic diseases from the basic customs duty ...

Adding Seagen's four approved oncology drugs – Adcetris (brentuximab vedotin) for blood cancers, Padcev (enfortumab vedotin) for bladder cancer and cervical cancer therapy Tivdak (tisotumab ...

Moreover, Ryoncil is not definitively preferred over other options after ruxolitinib, such as mycophenolate, sirolimus, and brentuximab vedotin. How preferred Ryoncil is will probably depend on ...